Peter Greenleaf, Aurinia CEO

Af­ter pass­ing on Ac­celeron, Bris­tol My­ers eyes bolt-on ac­qui­si­tion of au­toim­mune spe­cial­ist — re­port

Bris­tol My­ers Squibb is look­ing to beef up its au­toim­mune port­fo­lio by scoop­ing up Au­rinia Phar­ma­ceu­ti­cals, Bloomberg re­port­ed.

The re­cent over­tures to Au­rinia, re­layed by anony­mous in­sid­ers, came just as Bris­tol My­ers turned down buy­out talks with part­ners at Ac­celeron — which Mer­ck ul­ti­mate­ly struck a deal to ac­quire for $11.5 bil­lion. Bris­tol My­ers has re­port­ed­ly de­cid­ed to cash out on its mi­nor­i­ty stake, like­ly bag­ging $1.3 bil­lion in the process, while keep­ing the roy­al­ty deals on two of Ac­celeron’s blood dis­or­der drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.